KR20160070106A - Plk-4 억제제의 염 및 결정체들 - Google Patents

Plk-4 억제제의 염 및 결정체들 Download PDF

Info

Publication number
KR20160070106A
KR20160070106A KR1020167012155A KR20167012155A KR20160070106A KR 20160070106 A KR20160070106 A KR 20160070106A KR 1020167012155 A KR1020167012155 A KR 1020167012155A KR 20167012155 A KR20167012155 A KR 20167012155A KR 20160070106 A KR20160070106 A KR 20160070106A
Authority
KR
South Korea
Prior art keywords
compound
salt
fumaric acid
acid salt
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167012155A
Other languages
English (en)
Korean (ko)
Inventor
피터 브렌트 샘슨
미클로시 페헤르
하인즈 더블유 폴스
Original Assignee
유니버시티 헬스 네트워크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 헬스 네트워크 filed Critical 유니버시티 헬스 네트워크
Priority to KR1020217036751A priority Critical patent/KR102395737B1/ko
Publication of KR20160070106A publication Critical patent/KR20160070106A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020167012155A 2013-10-18 2014-10-17 Plk-4 억제제의 염 및 결정체들 Ceased KR20160070106A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217036751A KR102395737B1 (ko) 2013-10-18 2014-10-17 Plk-4 억제제의 염 및 결정체들

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361892564P 2013-10-18 2013-10-18
US61/892,564 2013-10-18
PCT/CA2014/051001 WO2015054793A1 (en) 2013-10-18 2014-10-17 Salt and crystal forms of plk-4 inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217036751A Division KR102395737B1 (ko) 2013-10-18 2014-10-17 Plk-4 억제제의 염 및 결정체들

Publications (1)

Publication Number Publication Date
KR20160070106A true KR20160070106A (ko) 2016-06-17

Family

ID=52827507

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020227015022A Ceased KR20220063299A (ko) 2013-10-18 2014-10-17 Plk-4 억제제의 염 및 결정체들
KR1020217036751A Active KR102395737B1 (ko) 2013-10-18 2014-10-17 Plk-4 억제제의 염 및 결정체들
KR1020167012155A Ceased KR20160070106A (ko) 2013-10-18 2014-10-17 Plk-4 억제제의 염 및 결정체들

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020227015022A Ceased KR20220063299A (ko) 2013-10-18 2014-10-17 Plk-4 억제제의 염 및 결정체들
KR1020217036751A Active KR102395737B1 (ko) 2013-10-18 2014-10-17 Plk-4 억제제의 염 및 결정체들

Country Status (27)

Country Link
US (5) US9884855B2 (enExample)
EP (1) EP3057965B1 (enExample)
JP (1) JP6492072B2 (enExample)
KR (3) KR20220063299A (enExample)
CN (2) CN113248486A (enExample)
AU (1) AU2014336929B9 (enExample)
CA (1) CA2926845C (enExample)
CY (1) CY1121484T1 (enExample)
DK (1) DK3057965T3 (enExample)
EA (1) EA031569B1 (enExample)
ES (1) ES2718603T3 (enExample)
HR (1) HRP20190564T1 (enExample)
HU (1) HUE043194T2 (enExample)
IL (1) IL245038B (enExample)
LT (1) LT3057965T (enExample)
ME (1) ME03377B (enExample)
MX (1) MX359069B (enExample)
NZ (1) NZ718744A (enExample)
PL (1) PL3057965T3 (enExample)
PT (1) PT3057965T (enExample)
RS (1) RS58413B1 (enExample)
SG (1) SG11201602783SA (enExample)
SI (1) SI3057965T1 (enExample)
SM (1) SMT201900124T1 (enExample)
TR (1) TR201902875T4 (enExample)
TW (1) TWI659952B (enExample)
WO (1) WO2015054793A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481525B2 (en) 2009-04-06 2013-07-09 University Of Health Network Kinase inhibitors and method of treating cancer with same
TWI516262B (zh) 2010-04-06 2016-01-11 健康網路大學 激酶抑制劑及以其治療癌症的方法
LT3057965T (lt) 2013-10-18 2019-03-12 University Health Network Plk-4 inhibitoriaus druska ir jos kristalinės formos
TWI845482B (zh) * 2017-09-08 2024-06-21 加拿大健康網路大學 用於抑制類polo激酶4之組合療法
KR20220004102A (ko) * 2019-04-24 2022-01-11 유니버시티 헬스 네트워크 Plk4 억제제 (1r,2s)-(e)-2-(3-(4-((시스-2,6-디메틸모르폴리노)메틸)스티릴)-1h-이미다졸-6-일)-5'-메톡시스피로[시클로프로판-1,3'-인돌린]-2'-온 푸마레이트의 결정 형태 s4
KR20220124177A (ko) * 2019-12-06 2022-09-13 유니버시티 헬스 네트워크 급성 골수성 백혈병 또는 골수형성이상증후군의 치료방법
EP4337198A4 (en) 2021-05-11 2025-04-16 Oric Pharmaceuticals, Inc. POLO-TYPE 4 KINASE INHIBITORS

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2483323A (en) * 1945-08-01 1949-09-27 Kay Fries Chemicals Inc Method of preparing phenyl ethyl alcohol
WO2004037247A1 (en) 2002-10-21 2004-05-06 Irm Llc Oxindoles with anti-hiv activity
DE102005005395A1 (de) * 2005-02-03 2006-08-10 Schering Aktiengesellschaft Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
GB0606234D0 (en) * 2006-03-29 2006-05-10 Pliva Istrazivanje I Razvoj D Pharmaceutically acceptable salts and polymorphic forms
EP2148740A4 (en) * 2007-03-23 2012-10-31 Agency Science Tech & Res Palladium catalysts
EP2205241B1 (en) * 2007-09-25 2014-05-21 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
EP2235004A4 (en) * 2007-12-21 2011-05-04 Univ Health Network INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL-SUBSTITUTED INDOLUND DERIVATIVES AS A KINASE-HEMMER FOR CANCER TREATMENT
US8481525B2 (en) * 2009-04-06 2013-07-09 University Of Health Network Kinase inhibitors and method of treating cancer with same
CN102428086B (zh) 2009-04-29 2014-08-20 内尔维阿诺医学科学有限公司 Cdk抑制剂的盐类
TWI516262B (zh) * 2010-04-06 2016-01-11 健康網路大學 激酶抑制劑及以其治療癌症的方法
ES2706066T3 (es) 2010-07-02 2019-03-27 Univ Health Network Procedimiento dirigido a enfermedades mutantes con PTEN y composiciones para las mismas
WO2012048411A1 (en) * 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
KR20130105675A (ko) * 2010-11-25 2013-09-25 라티오팜 게엠베하 아파티닙의 신규 염 및 다형
CA2850394C (en) * 2011-10-12 2019-05-21 University Health Network Indazole compounds as kinase inhibitors and method of treating cancer with same
MX357763B (es) 2013-10-18 2018-07-23 Univ Health Network Tratamiento para cancer pancreatico.
LT3057965T (lt) 2013-10-18 2019-03-12 University Health Network Plk-4 inhibitoriaus druska ir jos kristalinės formos

Also Published As

Publication number Publication date
MX359069B (es) 2018-09-12
CN113248486A (zh) 2021-08-13
CY1121484T1 (el) 2020-05-29
NZ718744A (en) 2021-07-30
EP3057965A4 (en) 2017-05-24
JP2016537326A (ja) 2016-12-01
EA201690755A1 (ru) 2016-09-30
US11667627B2 (en) 2023-06-06
CA2926845A1 (en) 2015-04-23
KR20210137251A (ko) 2021-11-17
US10472353B2 (en) 2019-11-12
SG11201602783SA (en) 2016-05-30
IL245038B (en) 2019-11-28
US20160264559A1 (en) 2016-09-15
CN105764899A (zh) 2016-07-13
ME03377B (me) 2020-01-20
KR102395737B1 (ko) 2022-05-10
PL3057965T3 (pl) 2019-08-30
SMT201900124T1 (it) 2019-05-10
LT3057965T (lt) 2019-03-12
TW201609717A (zh) 2016-03-16
HRP20190564T1 (hr) 2019-05-17
US10919886B2 (en) 2021-02-16
US20180155335A1 (en) 2018-06-07
WO2015054793A1 (en) 2015-04-23
AU2014336929B9 (en) 2019-03-21
TWI659952B (zh) 2019-05-21
MX2016004963A (es) 2016-06-28
JP6492072B2 (ja) 2019-03-27
CA2926845C (en) 2023-06-13
SI3057965T1 (sl) 2019-04-30
RS58413B1 (sr) 2019-04-30
AU2014336929B2 (en) 2018-11-22
EA031569B1 (ru) 2019-01-31
US20200140428A1 (en) 2020-05-07
EP3057965A1 (en) 2016-08-24
PT3057965T (pt) 2019-04-23
IL245038A0 (en) 2016-05-31
US9884855B2 (en) 2018-02-06
TR201902875T4 (tr) 2019-03-21
US20190248775A1 (en) 2019-08-15
ES2718603T3 (es) 2019-07-03
EP3057965B1 (en) 2019-01-02
KR20220063299A (ko) 2022-05-17
CN105764899B (zh) 2021-06-01
HUE043194T2 (hu) 2019-08-28
DK3057965T3 (en) 2019-04-01
US10392374B2 (en) 2019-08-27
US20210269428A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
US11667627B2 (en) Salt and crystal forms of PLK-4 inhibitor
AU2014336929A1 (en) Salt and crystal forms of PLK-4 inhibitor
US11878980B2 (en) Solid forms of TTK inhibitor
HK1227404A1 (en) Salt and crystal forms of plk-4 inhibitor
HK1227404B (en) Salt and crystal forms of plk-4 inhibitor
HK40007702A (en) Solid forms of ttk inhibitor
HK40007702B (en) Solid forms of ttk inhibitor

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160509

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190524

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20201202

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210618

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20201202

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20210618

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20210126

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20211008

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20210908

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20210618

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20210126

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20201202

X601 Decision of rejection after re-examination
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20211110

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20211110

WITB Written withdrawal of application